Wellness After Breast Cancer Study

The Wellness After Breast Cancer (WABC) Study is a cross-sectional study conducted between March 2008 and July 2009 at the Rowan Breast Cancer Center of the Abramson Cancer Center of the University of Pennsylvania (Philadelphia, PA, USA). Eligibility criteria included postmenopausal status (≥12 months of amenorrhea), history of histologically-confirmed hormone receptor-positive breast cancer, AJCC stages 0 to III, and exposure to a third-generation aromatase inhibitor (anastrozole, letrozole, or exemestane). Additional eligibility criteria included completion of all chemotherapy and/or radiotherapy at least one month prior to enrollment, approval of the patient's primary oncologist, and ability to provide informed consent. Research assistants screened medical records and approached potential patients for enrollment at their regular follow-up appointments. After informed consent was obtained, each participant completed a self-administered survey. Peripheral blood was collected; whole blood and serum samples were banked at -80°C for genetic and biomarker analysis, respectively. The study was approved by the Institutional Review Board of the University of Pennsylvania.